Peptide Cancer Vaccine Market Size and Share is expected at 11.2% CAGR Rise Will Hit 10.07 Billion by 2028
Market Synopsis:
Global Peptide Cancer Vaccine Market is valued at USD 4.72 Billion in 2021 and is projected to attain a value of USD 10.07 Billion by 2028 at a CAGR of 11.2% during the forecast period, 2022–2028. Peptide Cancer Vaccine help to elicit and grow tumor-specific T lymphocytes that can control or eliminate tumors. One or more short or long amino acid sequences serve as tumor antigens in the vaccination, which is coupled with a vaccine adjuvant.
Clinical experiments using peptide cancer vaccines have yielded disappointing results in the recent past. As a result, peptide vaccine researchers have deemed this therapy obsolete and declared it no longer viable for cancer treatment. However, as knowledge of the crucial function of immunological adjuvants, vaccine administration methods, and T cell dynamics has improved, this approach to the treatment of malignant illnesses has resurfaced.
The rising prevalence of cancer and the failure of traditional cancer treatments to adequately treat the disease has fueled demand for innovative immunotherapy-based therapeutics such Peptide Cancer Vaccine. According to the National Cancer Institute, 16.8 million new instances of cancer were diagnosed in the United States in 2016, with an estimated 595,690 deaths from the disease. By 2024, the number of cancer patients is predicted to reach 19 million. In addition, the World Health Organization (WHO) recorded around 14 million cancer cases and 8.2 million cancer-related deaths in 2012. Lung, colorectal, prostate, cervical, and breast cancer were among the most common occurrences, which has resulted in a substantial increase in demand for peptide vaccines, which has aided in the growth of the Peptide Cancer Vaccine industry.
Key Findings:
- The personalized peptide vaccine sub-segment is anticipated to dominate the segment for Peptide Cancer Vaccine Market and growing at a substantial Compound Annual Growth Rate (CAGR). This is owing to improved response rates of the personalized peptide vaccine and safety.
- The breast cancer sub-segment held a market significant share in 2021. This is because of Peptide Cancer Vaccines have proven to be less toxic and more target responsive to breast cancer patients.
- North America is the largest regional segment. This surge is attributed to the rising demand of vaccines in developed economies such as U.S. and Canada. This is attributed to presence of a high number of top pharmaceutical and biotech companies in this region such as Pfizer, Inc., Novartis, Merck, GlaxoSmithKline, and Roche. Moreover, increasing prevalence of cancer is also expected to foster the market growth in this region.
Market Segmentation:
The Global Peptide Cancer Vaccine Market can be segmented by Application into Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Gastric Cancer, Prostate Cancer and Breast Cancer. Based on Type, into Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine and Others. Based on Region, the Peptide Cancer Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Browse market data Tables and Figures spread through 122 Pages and in-depth TOC on "Peptide Cancer Vaccine Market by Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), by Type (Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)" View detailed Research Report here - https://www.vantagemarketresearch.com/industry-report/peptide-cancer-vaccine-market-1323
Key Players:
Major players operating in the global Peptide Cancer Vaccine market include TapImmune (US), Merck (US), BrightPath Biotherapeutics (Japan), Sellas (US), BioLife Science (US), Boston Biomedical (US), VAXON Biotech (France), Lytix Biopharma (Norway), ISA Pharmaceuticals (Netherlands), Generex Biotechnology (Canada), OncoTherapy Science (Japan), Enzo Life Science (US), Antigen Express (US), Immatics Biotechnologies (US), Immune Design (US), Immunomedics (US), Galena Biopharma (US), Generex Biotechnology Corporation (Canada), and Ultimovacs (Norway).
The Peptide Cancer Vaccine market is segmented as follows:
- Application
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- Type
- Personalized Peptide Vaccine
- Peptide-Pulsed Dendritic Cancer Vaccine
- Peptide Cocktail Type
- Multivalent Peptide Vaccine
- Others
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
By Application (Revenue: USD Billion, 2016 - 2028)
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
By Type (Revenue: USD Billion, 2016 - 2028)
- Personalized Peptide Vaccine
- Peptide-Pulsed Dendritic Cancer Vaccine
- Peptide Cocktail Type
- Multivalent Peptide Vaccine
- Others
By Region (Revenue: USD Billion, 2016 - 2028)
- North America
o U.S.
o Canada
o Mexico
- Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe
- Asia Pacific
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific
- Latin America
o Brazil
o Argentina
o Rest of Latin America
- Middle East & Africa
o GCC Countries
o South Africa
o Rest of Middle East & Africa
Contact:
Manager
Phone : 1-20) 380-9727
Email : coralia.joe@vantagemarketresearch.com